Duration of dual antiplatelet therapy after various drug-eluting stent implantation

International Journal of Cardiology

Volumn 215, Issue , 2016, Pages 157-166

  Sharma, Abhishek ^a   Sharma, Samin K ^b   Vallakati, Ajay ^c   Garg, Akash ^b   Lavie, Carl J ^d   Mukherjee, Debabrata ^e   Marmur, Jonathan D ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c METROHEALTH MEDICAL CENTER   (United States)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Drug eluting stents; Dual anti platelet therapy

Indexed keywords

EVEROLIMUS; PACLITAXEL; RAPAMYCIN; ANTITHROMBOCYTIC AGENT;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; EVEROLIMUS ELUTING CORONARY STENT; HEART INFARCTION; HUMAN; MORTALITY; PACLITAXEL ELUTING CORONARY STENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIROLIMUS ELUTING CORONARY STENT; ST SEGMENT; STENT THROMBOSIS; TREATMENT DURATION; DRUG ADMINISTRATION; META ANALYSIS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROCEDURES; TREATMENT OUTCOME; TRENDS;

DRUG ADMINISTRATION SCHEDULE; DRUG-ELUTING STENTS; HUMANS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84964562893     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.04.118     Document Type: Article

References (31)

1. C.L. Grines, R.O. Bonow, D.E. Casey Jr., T.J. Gardner, P.B. Lockhart, D.J. Moliterno, P. O'Gara, and P. Whitlow Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians J. Am. Coll. Cardiol. 49 6 2007 Feb 13 734 739
2. G.N. Levine, E.R. Bates, J.C. Blankenship, S.R. Bailey, J.A. Bittl, B. Cercek, C.E. Chambers, S.G. Ellis, R.A. Guyton, S.M. Hollenberg, U.N. Khot, R.A. Lange, L. Mauri, R. Mehran, I.D. Moussa, D. Mukherjee, B.K. Nallamothu, H.H. Ting, American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines, and Society for Cardiovascular Angiography and Interventions 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions J. Am. Coll. Cardiol. 58 24 2011 Dec 6 e44 122
3. Task Force members, S. Windecker, P. Kolh, F. Alfonso, C. JP, J. Cremer, V. Falk, G. Filippatos, C. Hamm, S.J. Head, P. Jüni, A.P. Kappetein, A. Kastrati, J. Knuuti, U. Landmesser, G. Laufer, F.J. Neumann, D.J. Richter, P. Schauerte, M. Sousa Uva, G.G. Stefanini, D.P. Taggart, L. Torracca, M. Valgimigli, W. Wijns, and Witkowski 2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Eur. Heart J. 35 37 2014 Oct 1 2541 2619
4. M.C John, R. Wessely, A. Kastrati, A. Schömig, M. Joner, M. Uchihashi, J. Crimins, S. Lajoie, F.D. Kolodgie, H.K. Gold, R. Virmani, and A.V. Finn Differential healing responses in polymer- and nonpolymer-based sirolimus-eluting stents JACC Cardiovasc. Interv. 1 5 2008 Oct 535 544
5. R. Jabara, N. Chronos, D. Conway, W. Molema, and K. Robinson Evaluation of a novel slow-release paclitaxel-eluting stent with a bioabsorbable polymeric surface coating JACC Cardiovasc Interv. 1 1 2008 Feb 81 87
6. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, and PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann. Intern. Med. 151 4 2009 Aug 18 264 269 W64
7. H.C. Gwon, J.Y. Hahn, K.W. Park, Y.B. Song, I.H. Chae, D.S. Lim, K.R. Han, J.H. Choi, S.H. Choi, H.J. Kang, B.K. Koo, T. Ahn, J.H. Yoon, M.H. Jeong, T.J. Hong, W.Y. Chung, Y.J. Choi, S.H. Hur, H.M. Kwon, D.W. Jeon, B.O. Kim, S.H. Park, N.H. Lee, H.K. Jeon, Y. Jang, and H.S. Kim Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the efficacy of Xience/Promus versus cypher to reduce late loss after stenting (EXCELLENT) randomized, multicenter study Circulation 125 3 2012 Jan 24 505 513
8. M. Valgimigli, G. Campo, M. Monti, P. Vranckx, G. Percoco, C. Tumscitz, F. Castriota, F. Colombo, M. Tebaldi, G. Fucà, M. Kubbajeh, E. Cangiano, M. Minarelli, A. Scalone, C. Cavazza, A. Frangione, M. Borghesi, J. Marchesini, G. Parrinello, and R. Ferrari Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial Circulation 125 16 2012 Apr 24 2015 2026
9. L. Mauri, D.J. Kereiakes, R.W. Yeh, P. Driscoll-Shempp, D.E. Cutlip, P.G. Steg, S.L. Normand, E. Braunwald, S.D. Wiviott, D.J. Cohen, D.R. Holmes Jr., M.W. Krucoff, J. Hermiller, H.L. Dauerman, D.I. Simon, D.E. Kandzari, K.N. Garratt, D.P. Lee, T.K. Pow, P. Ver Lee, M.J. Rinaldi, J.M. Massaro, and DAPT Study Investigators Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents N. Engl. J. Med. 371 23 2014 Dec 4 2155 2166
10. M. Gilard, P. Barragan, A.A. Noryani, H.A. Noor, T. Majwal, T. Hovasse, P. Castellant, M. Schneeberger, L. Maillard, E. Bressolette, J. Wojcik, N. Delarche, D. Blanchard, B. Jouve, O. Ormezzano, F. Paganelli, G. Levy, J. Sainsous, D. Carrie, A. Furber, J. Berland, O. Darremont, H. Le Breton, A. Lyuycx-Bore, A. Gommeaux, C. Cassat, A. Kermarrec, P. Cazaux, P. Druelles, R. Dauphin, J. Armengaud, P. Dupouy, D. Champagnac, P. Ohlmann, K. Endresen, H. Benamer, K. RG, I. Ungi, J. Boschat, and M. MC Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin: ITALIC, a randomized multicenter trial J. Am. Coll. Cardiol. 65 8 2015 Mar 3 777 786
11. F. Feres, R.A. Costa, A. Abizaid, M.B. Leon, J.A. Marin-Neto, R.V. Botelho, S.B. King 3rd, M. Negoita, M. Liu, J.E. de Paula, J.A. Mangione, G.X. Meireles, H.J. Castello Jr., E.L. Nicolela Jr., M.A. Perin, F.S. Devito, A. Labrunie, D. Salvadori Jr., M. Gusmão, R. Staico, J.R. Costa Jr., J.P. de Castro, A.S. Abizaid, D.L. Bhatt, and OPTIMIZE Trial Investigators Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial J. Am. Med. Assoc. 310 23 2013 Dec 18 2510 2522
12. A. Colombo, A. Chieffo, A. Frasheri, R. Garbo, M. Masotti-Centol, N. Salvatella, J.F. Oteo Dominguez, L. Steffanon, G. Tarantini, P. Presbitero, A. Menozzi, E. Pucci, J. Mauri, B.M. Cesana, G. Giustino, and G. Sardella Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial J. Am. Coll. Cardiol. 64 20 2014 Nov 18-25 2086 2097
13. G. Giustino, U. Baber, S. Sartori, R. Mehran, I. Mastoris, A.S. Kini, S.K. Sharma, S.J. Pocock, and G.D. Dangas Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials J. Am. Coll. Cardiol. 65 13 2015 Apr 7 1298 1310
14. E.P. Navarese, F. Andreotti, V. Schulze, M. Kołodziejczak, A. Buffon, M. Brouwer, F. Costa, M. Kowalewski, G. Parati, G.Y. Lip, M. Kelm, and M. Valgimigli Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials BMJ 350 2015 Apr 16 h1618
15. T. Palmerini, U. Benedetto, L. Bacchi-Reggiani, D. Della Riva, G. Biondi-Zoccai, F. Feres, A. Abizaid, M.K. Hong, B.K. Kim, Y. Jang, H.S. Kim, K.W. Park, P. Genereux, D.L. Bhatt, C. Orlandi, S. De Servi, M. Petrou, C. Rapezzi, and G.W. Stone Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials Lancet 385 9985 2015 Jun 13 2371 2382
16. S. Elmariah, L. Mauri, G. Doros, B.Z. Galper, K.E. O'Neill, P.G. Steg, D.J. Kereiakes, and R.W. Yeh Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis Lancet 385 9970 2015 Feb 28 792 798
17. G. El-Hayek, F. Messerli, S. Bangalore, M.K. Hong, E. Herzog, A. Benjo, and J.E. Tamis-Holland Meta-analysis of randomized clinical trials comparing short-term versus long-term dual antiplatelet therapy following drug-eluting stents Am. J. Cardiol. 114 2 2014 Jul 15 236 242
18. T. Palmerini, D. Sangiorgi, M. Valgimigli, G. Biondi-Zoccai, F. Feres, A. Abizaid, R.A. Costa, M.K. Hong, B.K. Kim, Y. Jang, H.S. Kim, K.W. Park, A. Mariani, D. Della Riva, P. Genereux, M.B. Leon, D.L. Bhatt, U. Bendetto, C. Rapezzi, and G.W. Stone Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis J. Am. Coll. Cardiol. 65 11 2015 Mar 24 1092 1102
19. R. Goldberg, J.M. Gore, B. Barton, and J. Gurwitz Individual and composite study endpoints: separating the wheat from the chaff Am. J. Med. 127 5 2014 May 379 384
20. A. Habib, and A.V. Finn Endothelialization of drug eluting stents and its impact on dual anti-platelet therapy duration Pharmacol. Res. 93 2015 Mar 22 27
21. S.O. Marx, and A.R. Marks Bench to bedside: the development of rapamycin and its application to stent restenosis Circulation 104 8 2001 Aug 21 852 855
22. M. Pfisterer, H.P. Brunner-La Rocca, P.T. Buser, P. Rickenbacher, P. Hunziker, C. Mueller, R. Jeger, F. Bader, S. Osswald, C. Kaiser, and BASKET-LATE Investigators Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents J. Am. Coll. Cardiol. 48 12 2006 Dec 19 2584 2591
23. G.G. Biondi-Zoccai, M. Lotrionte, P. Agostoni, A. Abbate, M. Fusaro, F. Burzotta, L. Testa, I. Sheiban, and G. Sangiorgi A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease Eur. Heart J. 27 22 2006 Nov 2667 2674
24. A.V. Finn, M. Joner, G. Nakazawa, F. Kolodgie, J. Newell, M.C. John, H.K. Gold, and R. Virmani Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization Circulation 115 18 2007 May 8 2435 2441
25. M. Joner, G. Nakazawa, A.V. Finn, S.C. Quee, L. Coleman, E. Acampado, P.S. Wilson, K. Skorija, Q. Cheng, X. Xu, H.K. Gold, F.D. Kolodgie, and R. Virmani Endothelial cell recovery between comparator polymer-based drug-eluting stents J. Am. Coll. Cardiol. 52 5 2008 Jul 29 333 342
26. D.R. Holmes Jr., D.J. Kereiakes, S. Garg, P.W. Serruys, G.J. Dehmer, S.G. Ellis, D.O. Williams, T. Kimura, and D.J. Moliterno Stent thrombosis J. Am. Coll. Cardiol. 56 17 2010 Oct 19 1357 1365
27. F. Otsuka, M. Vorpahl, M. Nakano, J. Foerst, J.B. Newell, K. Sakakura, R. Kutys, E. Ladich, A.V. Finn, F.D. Kolodgie, and R. Virmani Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans Circulation 129 2 2014 Jan 14 211 223
28. H. Dores, L. Raposo, R. Campante Teles, C. Machado, S. Leal, P. Araújo Gonçalves, H. Mesquita Gabriel, M. Sousa Almeida, and M. Mendes Stent thrombosis with second- versus first-generation drug-eluting stents in real-world percutaneous coronary intervention: analysis of 3806 consecutive procedures from a large-volume single-center prospective registry J. Invasive Cardiol. 25 7 2013 Jul 330 336
29. G. Montalescot, D. Brieger, A.J. Dalby, S.J. Park, and R. Mehran Duration of dual antiplatelet therapy after coronary stenting: a review of the evidence J. Am. Coll. Cardiol. 66 7 2015 Aug 18 832 847
30. A. Eisen, and D.L. Bhatt Antiplatelet therapy: defining the optimal duration of DAPT after PCI with DES Nat. Rev. Cardiol. 12 8 2015 Aug 445 446
31. R. Mehran, G. Giustino, and U. Baber DAPT duration after DES: what is the "mandatory" duration? J. Am. Coll. Cardiol. 65 11 2015 Mar 24 1103 1106